Recently, GLP-1 agonists have become one of the first-line pharmacological treatments for obesity due to their potent ability to reduce gastric emptying, glucagon secretion and weight gain [95]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.